Skip to main content
Smitha Rao

Smitha Rao

Researcher

Oct 8, 2026

11:21
Yeah.
11:21
You have to address inflammation.
11:23
It's critical.
11:24
Second, I would say at a cellular level you do see NAD+ go down.
11:28
You see mitochondrial, uh, aging.
11:30
That also impacts your skin, for sure.
11:33
Third, I think is a far more interesting area, is, um, barrier strength.

14 MINS LATER

25:12
It's working
6:40
Mm.
6:41
So I've been in biotech all my career, right? This is the only thing that I know.
6:44
Biotech 1.0 was creating bio cells, you know, uh, technologies from cells, and it focused on higher value products, like your peptides, which were typically thousands of dollars a kilo, right? You use...
6:58
It was, it's a playbook from pharma.
7:00
You use biotechnology, really create these high value compounds.
7:05
And if you think about a skincare formulation, the actives cost the most amount of money, right? You put it in very small concentrations, but it had really great impact 'cause it drove your clinical efficacy.
7:16
Now it's biotech 2.0, and this is very, very exciting because now it's biotech at scale.

15 MINS LATER

22:26
Mm.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.